Translationale Tumorforschung

Malignant Tumors of Soft Tissue and Bone

More than 70 types of soft tissue neoplasms have been defined by the WHO classification. Morphologically, sarcomas can be subdivided into two major subgroups: tumors with a non-pleomorphic morphology and those with a pleomorphic phenotype. Non-pleomorphic sarcomas more often carry specific molecular aberrations whereas pleomorphic sarcomas frequently display complex karyotypes.


Three major types of genomic alterations occur in sarcomas:

  • Reciprocal translocations (~15%)
  • Specific mutations (~25%) 
  • Amplifications (~10%)

While chromosomal translocations lead to the formation of chimeric fusion genes, the resulting fusion proteins function frequently as transcription factors. Specific mutations are often found in genes encoding tyrosine kinases. Amplifications mainly affect genes which encode important modulators in cell cycle control.


Our research projects in the field of soft tissue and bone pathology focus on:

  • The diagnostic, prognostic and/or predictive value of specific markers and genomic alterations in malignant tumors of soft tissue and bone
  • The translational exploration of signaling pathways in particular subgroups of soft tissue sarcomas aiming at a better understanding of the underlying tumor biology and the definition of novel therapeutic approaches.

Selected research projects:


Wolfgang Hartmann, Prof. Dr. med.
Deputy director of the Gerhard-Domagk-Institute of Pathology, Principal Investigator

ORCID: 0000-0002-7609-5021
ResearcherID: G-1893-2017

T +49 251 83-58479
F +49 251 83-57559

Marcel Trautmann, Dr. rer. nat.
Junior research group leader, Principal Investigator

ORCID: 0000-0002-5842-1196
ResearcherID: B-4627-2015

T +49 251 83-57623
F +49 251 83-57559

(in alphabetical order)

  • Alina Hildebrand, MedK-PhD student (Dr. med.)
  • Charlotte Sohlbach, Technical Assistant / Email
  • Danielle Brandes, Graduate Student (M.Sc.) / Email
  • Esther-Pia Jansen, Technical Assistant / Email
  • Ilka Isfort, PhD student (Dr. rer. nat.) / Email
  • Konrad Steinestel, PD Dr. med. Dr. rer. nat. / Email
  • Magdalene Alice Cyra, PhD student (Dr. rer. nat.) / Email
  • Ruth Berthold, PhD student (Dr. rer. nat.) / Email
  • Sandra Elges, Dr. med. (Resident) / Email
  • Sebastian Huss, PD Dr. med. (Consultant) / Email


> Hartmann W. (PubMed), Huss S. (PubMed), Trautmann M. (PubMed) Wardelmann E. (PubMed)

Trautmann, M., Menzel, J., Bertling, C., Cyra, M., Isfort, I., Steinestel, K., Elges, S., Grünewald, I., Altvater, B., Rössig, C., Fröhling, S., Hafner, S., Simmet, T., Åman, P., Wardelmann, E., Huss, S. and  Hartmann, W. FUS-DDIT3 fusion protein driven IGF-IR signaling is a therapeutic target in myxoid liposarcoma. Clinical Cancer Research 2017; Published OnlineFirst July 28, doi: 10.1158/1078-0432.CCR-17-0130  /  Read more

Grünewald, I., Trautmann, M., Busch, A., Bauer, L., Huss, S., Schweinshaupt, P., Vollbrecht, C., Odenthal, M., Quaas, A., Buttner, R., Meyer, M. F., Beutner, D., Huttenbrink, K. B., Wardelmann, E., Stenner, M., and Hartmann, W. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas. Oncotarget. 2016;7(46):75261-72.  /  Read more

Agelopoulos, K., Richter, G. H., Schmidt, E., Dirksen, U., von Heyking, K., Moser, B., Klein, H. U., Kontny, U., Dugas, M., Poos, K., Korsching, E., Buch, T., Weckesser, M., Schulze, I., Besoke, R., Witten, A., Stoll, M., Kohler, G., Hartmann, W., Wardelmann, E., Rossig, C., Baumhoer, D., Jurgens, H., Burdach, S., Berdel, W. E., and Muller-Tidow, C. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. Clinical Cancer Research, 2015. 21(21):4935-46.  /  Read more

Sievers, E., Trautmann, M., Kindler, D., Huss, S., Gruenewald, I., Dirksen, U., Renner, M., Mechtersheimer, G., Pedeutour, F., Aman, P., Nishio, J., Schildhaus, H. U., Kirfel, J., Schirmacher, P., Wardelmann, E., Buettner, R., and Hartmann, W. SRC inhibition represents a potential therapeutic strategy in liposarcoma. Int J Cancer. 2015;137(11):2578-88.  /  Read more

Trautmann, M., Sievers, E., Aretz, S., Kindler, D., Michels, S., Friedrichs, N., Renner, M., Kirfel, J., Steiner, S., Huss, S., Koch, A., Penzel, R., Larsson, O., Kawai, A., Tanaka, S., Sonobe, H., Waha, A., Schirmacher, P., Mechtersheimer, G., Wardelmann, E., Buttner, R., and Hartmann, W. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene. 2014;33(42):5006-16.  /  Read more

Michels, S.*, Trautmann, M.*, Sievers, E., Kindler, D., Huss, S., Renner, M., Friedrichs, N., Kirfel, J., Steiner, S., Endl, E., Wurst, P., Heukamp, L., Penzel, R., Larsson, O., Kawai, A., Tanaka, S., Sonobe, H., Schirmacher, P., Mechtersheimer, G., Wardelmann, E., Buttner, R., and Hartmann, W. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Research. 2013;73(8):2518-28. *Authors contributed equally  /  Read more

Friedrichs, N., Trautmann, M., Endl, E., Sievers, E., Kindler, D., Wurst, P., Czerwitzki, J., Steiner, S., Renner, M., Penzel, R., Koch, A., Larsson, O., Tanaka, S., Kawai, A., Schirmacher, P., Mechtersheimer, G., Wardelmann, E., Buettner, R., and Hartmann, W. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer. 2011;129(7):1564-75.  /  Read more

Hartmann, W., Kuchler, J., Koch, A., Friedrichs, N., Waha, A., Endl, E., Czerwitzki, J., Metzger, D., Steiner, S., Wurst, P., Leuschner, I., von Schweinitz, D., Buettner, R., and Pietsch, T. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clinical Cancer Research, 2009. 15(14):4538-45.  /  Read more

Friedrichs, N., Kuchler, J., Endl, E., Koch, A., Czerwitzki, J., Wurst, P., Metzger, D., Schulte, J. H., Holst, M. I., Heukamp, L. C., Larsson, O., Tanaka, S., Kawai, A., Wardelmann, E., Buettner, R., Pietsch, T., and Hartmann, W. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol, 2008. 216(4):428-39.  /  Read more

Hartmann, W., Digon-Sontgerath, B., Koch, A., Waha, A., Endl, E., Dani, I., Denkhaus, D., Goodyer, C. G., Sorensen, N., Wiestler, O. D., and Pietsch, T. Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clinical Cancer Research, 2006. 12(10):3019-27.  /  Read more

Hartmann, W., Koch, A., Brune, H., Waha, A., Schuller, U., Dani, I., Denkhaus, D., Langmann, W., Bode, U., Wiestler, O. D., Schilling, K., and Pietsch, T. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol, 2005. 166(4):1153-62.  /  Read more


in alphabetical order:

  • Deutsche Forschungsgemeinschaft (DFG)
  • Deutsche Krebshilfe
  • Dr. Eberhard und Hilde Rüdiger Stiftung
  • GlaxoSmithKline Stiftung
  • Innovative Medical Research (IMF) - Medical Faculty of the Westfälische Wilhelms-University Münster
  • MedK - Medical Faculty of the Westfälische Wilhelms-Universität Münster
  • Wilhelm Sander-Stiftung



T (Lab):

+49 251 83-57626 or -58464

T (Office):

+49 251 83-55444 or -58461

F +49 251 83-57559

Visiting address (Google maps):

Domagkstr. 17

48149 Münster, Germany

Our cancer research lab is located at the Gerhard-Domagk-Institute of Pathology / University Hospital Münster (UKM), Germany